Skip to main content

Table 2 Risk factors for the development of diabetes at 12 months

From: Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies

  Odds ratio (95% CI) p value
Model 1
 Age, years 1.06 (0.93–1.24) 0.36
 Female sex 0.73 (0.24–2.01) 0.55
 Serum creatinine, mg/dL 0.83 (0.66–0.99) 0.040
 Initial PSL dose, mg/kg/day 3.32 (0.29–41.66) 0.34
 Concomitant cyclophosphamide use 0.29 (0.09–0.87) 0.027
Model 2
 Age, years 1.08 (0.94–1.26) 0.28
 Female sex 0.76 (0.25–2.09) 0.60
 Serum creatinine, mg/dL 0.86 (0.70–1.02) 0.09
 Initial PSL dose, mg/kg/day 1.26 (0.13–14.65) 0.85
 PSL dose at 12 months, mg/day 1.14 (1.00–1.35) 0.045
  1. CI confidential interval, PSL prednisolone